Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 2, 2012, Pages 222-226

  Miyaoka, Tsuyoshi ^a   Wake, Rei ^a   Furuya, Motohide ^a   Liaury, Kristian ^a   Ieda, Masa ^a   Kawakami, Kazunori ^a   Tsuchie, Keiko ^a   Taki, Michiyo ^a   Ishihara, Kotomi ^a   Araki, Tomoko ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Adjunctive therapy; Minocycline; Open label study; Psychotic depression

Indexed keywords

FLUVOXAMINE; MINOCYCLINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OPEN STUDY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84859571611     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.02.002     Document Type: Article

References (42)

1. Ahuja N., Carroll B.T. Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:968-969.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision,. 4th Edition.
3. Arakawa S., Shirayama Y., Fujita Y., Ishima T., Horio M., Muneoka K., Iyo M., Hashimoto K. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdale and no changes in BDNF levels in the hippoicampus at baseline. Prog Neuropsychopharmacol Biol Psychiatry 2012, 100:601-606.
4. Baptista T., Zarate J., Joober R., Colasante C., Beaulieu S., Paez X., et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus or antipsychotics. Curr Drug Targets 2004, 5:279-299.
5. Catapano-Friedman L. Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis. J Child Adolesc Psychopharmacol 2001, 11:205-206.
6. Coryell W. Psychotic depression. J Clin Psychiatry 1996, 57(Suppl. 3):27-31.
7. Coryell W., Lavori P., Endicott J., Keller M., Van Eerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up. Arch Gen Psychiatry 1987, 41:787-791.
8. Czeh B., Lucassen P.J. What causes the hipocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?. Eur Arch Psychiatry Clin Neurosci 2007, 257:250-260.
9. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:336-339.
10. Gaudiano B.A., Beevers C.G., Miller I.W. Differential response to combined treatment in patients with psychotic versus nonpsychotic major depression. J Nerv Ment Dis 2005, 193:625-628.
11. Gaudiano B.A., Miller I.W., Herbert J.D. The treatment of psychotic major depression: is there role for adjunctive psychotherapy?. Psychother Psychosom 2007, 76:271-277.
12. Guy W. ECDEU assessment manual for psychopharmacology-revised, Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramanual Research Programs 1976, 218-222.
13. Hamilton M. A rating scale for depression. J Neural Meurosug Psychiatry 1960, 23:56-61.
14. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1758-1759.
15. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
16. Hashimoto K., Ishima T. A novel target of action minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation. PLoS One 2010, 5:e15430.
17. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316.
18. Keller J., Schatzberg A.F., Maj M. Current issues in the classification of psychotic major depression. Schizophr Bull 2007, 33:877-885.
19. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav Brain Res 2009, 196:168-179.
20. Levine J., Cholestoy A., Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry 1996, 153:582.
21. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
22. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog NeuroPsychopharmacol Biol Psychiatry 1995, 19:11-13.
23. Maes M., Timyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24:27-53.
24. Matthews J.D., Stifert D.C., Denniger J.W., Park L., Fava M. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol 2009, 29:73-76.
25. Meyers B.S., Fint A.J., Rothschild A.J., Mulsant B.H., Whyte E.M., Peasley M., et al. STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression. The study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009, 66:838-847.
26. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008, 7:376-381.
27. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307.
28. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
29. Molina-Hernandez M., Tellez-Alcantara N.P., Perez Garcia J., Olivera-Lopez J.I., Jaramillo-Jaimes M.T. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:380-386.
30. Molina-Hernandez M., Tellez-Alcantara N.P., Perez Garcia J., Olivera-Lopez J.I., Jaramillo-Jaimes M.T. Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1660-1666.
31. O'Gonnor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Gastanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
32. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
33. Pae C.U., Marks D.M., Hsn C., Patkar A.A. Dose minocycline have antidepressant effect?. Biomed Pharmacother 2008, 62:308-311.
34. Parker G., Roy K., Hadzi-Pavlovic D., Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992, 24:17-24.
35. Perera T.D., Coplan J.D., Lisanby S.H., Lipira C.M., Arif M., Carpio C. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman promates. J Neurosci 2007, 27:4894-4901.
36. Ponzini S. Macrophages-mediated neurotoxic effects of intra-nigra manganese administration are attenuated by minocycline. Neurosci lett 2012, 506:136-140.
37. Sanchez C., Bogeso K.P., Ebert B., Renes E.H., Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004, 174:163-176.
38. Vythilingam M., Chen J., Bremmer J.D., Mazure C.M., Maciejewski P.K., Nelson J.C. Psychotic depression and mortality. Am J Psychiatry 2003, 160:574-576.
39. Wijkstra J., Limer J., Balk F., Geddes J., Nolen W. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2005, CD00444.
40. Wijkstra J., Burger H., Limer J., Balk F., Geddes J., Nolen W. Pharmacological treatment for psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006, 188:410-415.
41. Wijkstra J., Burger H., den Broek WW Va, Birkenhanger T.K., Janzing J.G.E., Bots M.P.M., et al. Treatment of unipolar psychotic depression: a randomized, double blind study comparing imipramine, venlataxine, and venltaxine plus quetiapine. Acta Psychiatr Scand 2010, 121:190-200.
42. Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1381-1393.